NASDAQ:PGNXProgenics Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Progenics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $3.69 +0.29 (+8.53 %) (As of 04/10/2020 06:36 AM ET) Add Compare Share Today's Range$3.39Now: $3.69▼$3.7150-Day Range$2.11MA: $3.79▼$5.1652-Week Range$1.89Now: $3.69▼$6.37Volume580,522 shsAverage Volume1.25 million shsMarket Capitalization$319.55 millionP/E RatioN/ADividend YieldN/ABeta2.16 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Progenics Pharmaceuticals, Inc., an oncology company, develops, manufactures, and commercializes pharmaceutical products and other technologies to target, diagnose, and treat cancer cancer in the United States and internationally. The company's product candidates include Azedra, a radiotherapeutic product candidate for the treatment of iobenguane scan positive, unresectable, and locally advanced or metastatic pheochromocytoma or paraganglioma for adult and pediatric patients; PyL, a clinical-stage fluorinated prostate specific membrane antigen (PSMA)-targeted PET/CT imaging agent for prostate cancer; and 1095, a PSMA-targeted Iodine-131 labeled small molecule, which is in Phase II clinical trial for the treatment of metastatic castration-resistant prostate cancer. Its product candidates also comprise PSMA TTC, a thorium-227 labeled PSMA-targeted antibody therapeutic that is in Phase I clinical trial for treatment of metastatic prostate cancer; and Leronlimab, a humanized monoclonal antibody, which is in Phase III development for the treatment of HIV infection. The company also offers Relistor-subcutaneous injection for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain or advanced-illness adult patients; Relistor tablets for the treatment of OIC in adults with chronic non-cancer pain; PSMA AI, an imaging analysis technology that uses artificial intelligence and machine learning to quantify and automate the reading of PSMA targeted imaging; and automated bone scan index, a software that quantifies the hotspots on bone scans and calculates the bone scan index value. It has license agreement with Salix Pharmaceuticals, Inc. for the development and commercialization of Relistor worldwide; and Amgen Fremont, Inc. to use its XenoMouse technology for generating human antibodies to PSMA. Progenics Pharmaceuticals, Inc. was founded in 1986 and is based in New York City, New York.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingProgenics Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.00, Progenics Pharmaceuticals has a potential upside of 225.2% from its current price of $3.69.Amount of Analyst CoverageProgenics Pharmaceuticals has received no research coverage in the past 90 days. Previous Next 2.6 Community Rank Outperform VotesProgenics Pharmaceuticals has received 413 “outperform” votes. (Add your “outperform” vote.)Underperform VotesProgenics Pharmaceuticals has received 376 “underperform” votes. (Add your “underperform” vote.)Community SentimentProgenics Pharmaceuticals has received 52.34% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote “Outperform” if you believe PGNX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe PGNX will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldProgenics Pharmaceuticals does not currently pay a dividend.Dividend GrowthProgenics Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Progenics Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.26% of the stock of Progenics Pharmaceuticals is held by insiders.Percentage Held by Institutions75.97% of the stock of Progenics Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Progenics Pharmaceuticals are expected to decrease by -52.94% in the coming year, from ($0.85) to ($0.40) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Progenics Pharmaceuticals is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Progenics Pharmaceuticals is -4.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioProgenics Pharmaceuticals has a P/B Ratio of 6.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.42 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:PGNX Previous Symbol CUSIP74318710 CIK835887 Webhttp://www.progenics.com/ Phone646-975-2500Debt Debt-to-Equity Ratio1.01 Current Ratio2.89 Quick Ratio2.89Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$34.99 million Price / Sales9.13 Cash FlowN/A Price / Cash FlowN/A Book Value$0.54 per share Price / Book6.83Profitability EPS (Most Recent Fiscal Year)($0.80) Net Income$-68,550,000.00 Net Margins-195.94% Return on Equity-106.04% Return on Assets-48.40%Miscellaneous Employees79 Outstanding Shares86,600,000Market Cap$319.55 million Next Earnings Date5/14/2020 (Estimated) OptionableOptionable Receive PGNX News and Ratings via Email Sign-up to receive the latest news and ratings for PGNX and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:PGNX Rates by TradingView Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions How has Progenics Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)? Progenics Pharmaceuticals' stock was trading at $3.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, PGNX shares have decreased by 3.1% and is now trading at $3.69. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Progenics Pharmaceuticals? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Progenics Pharmaceuticals in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Progenics Pharmaceuticals. When is Progenics Pharmaceuticals' next earnings date? Progenics Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Progenics Pharmaceuticals. How were Progenics Pharmaceuticals' earnings last quarter? Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Friday, March, 13th. The biotechnology company reported ($0.13) EPS for the quarter, beating the Zacks' consensus estimate of ($0.25) by $0.12. The biotechnology company earned $15.13 million during the quarter. Progenics Pharmaceuticals had a negative net margin of 195.94% and a negative return on equity of 106.04%. View Progenics Pharmaceuticals' earnings history. What price target have analysts set for PGNX? 3 equities research analysts have issued 1 year price targets for Progenics Pharmaceuticals' stock. Their forecasts range from $10.00 to $14.00. On average, they anticipate Progenics Pharmaceuticals' stock price to reach $12.00 in the next twelve months. This suggests a possible upside of 225.2% from the stock's current price. View analysts' price targets for Progenics Pharmaceuticals. Has Progenics Pharmaceuticals been receiving favorable news coverage? Press coverage about PGNX stock has been trending very negative recently, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Progenics Pharmaceuticals earned a media sentiment score of -3.3 on InfoTrie's scale. They also gave press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutProgenics Pharmaceuticals. Are investors shorting Progenics Pharmaceuticals? Progenics Pharmaceuticals saw a decrease in short interest in the month of February. As of February 28th, there was short interest totaling 5,430,000 shares, a decrease of 10.1% from the February 13th total of 6,040,000 shares. Based on an average daily trading volume, of 893,100 shares, the short-interest ratio is presently 6.1 days. Approximately 7.0% of the company's shares are sold short. View Progenics Pharmaceuticals' Current Options Chain. Who are some of Progenics Pharmaceuticals' key competitors? Some companies that are related to Progenics Pharmaceuticals include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Alexion Pharmaceuticals (ALXN), Seattle Genetics (SGEN), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS) and Exelixis (EXEL). What other stocks do shareholders of Progenics Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Progenics Pharmaceuticals investors own include Vonage (VG), Synergy Pharmaceuticals (SGYP), Exelixis (EXEL), Caterpillar (CAT), Novavax (NVAX), Imax (IMAX), Opko Health (OPK), Cara Therapeutics (CARA), Portola Pharmaceuticals (PTLA) and Dynavax Technologies (DVAX). Who are Progenics Pharmaceuticals' key executives? Progenics Pharmaceuticals' management team includes the following people: Mr. Mark R. Baker, CEO & Director (Age 64)Mr. Patrick Fabbio, Exec. VP & CFO (Age 51)Mr. Benedict Osorio, Chief Operating Officer (Age 62)Dr. Vivien Wong, Exec. VP of Devel. (Age 62)Mr. Bryce V. Tenbarge, Sr. VP of Commercial (Age 46) What is Progenics Pharmaceuticals' stock symbol? Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX." Who are Progenics Pharmaceuticals' major shareholders? Progenics Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include State of Alaska Department of Revenue (0.09%). Company insiders that own Progenics Pharmaceuticals stock include Lte Partners, Llc and Velan Capital, LP. View institutional ownership trends for Progenics Pharmaceuticals. Which institutional investors are buying Progenics Pharmaceuticals stock? PGNX stock was acquired by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue. Company insiders that have bought Progenics Pharmaceuticals stock in the last two years include Lte Partners, Llc, and Velan Capital, LP. View insider buying and selling activity for Progenics Pharmaceuticals. How do I buy shares of Progenics Pharmaceuticals? Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Progenics Pharmaceuticals' stock price today? One share of PGNX stock can currently be purchased for approximately $3.69. How big of a company is Progenics Pharmaceuticals? Progenics Pharmaceuticals has a market capitalization of $319.55 million and generates $34.99 million in revenue each year. The biotechnology company earns $-68,550,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Progenics Pharmaceuticals employs 79 workers across the globe. View additional information about Progenics Pharmaceuticals. What is Progenics Pharmaceuticals' official website? The official website for Progenics Pharmaceuticals is http://www.progenics.com/. How can I contact Progenics Pharmaceuticals? Progenics Pharmaceuticals' mailing address is ONE WORLD TRADE CENTER 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected] This page was last updated on 4/10/2020 by MarketBeat.com StaffFeatured Article: What are popular green investing opportunities?
